Join to View Full Profile
4450 31st Ave SFargo, ND 58104
Phone+1 701-280-2033
Fax+1 701-232-5578
Dr. Lillestol is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael Lillestol is an internist in Fargo, ND and is affiliated with multiple hospitals in the area, including Sanford Medical Center, Essentia Health, and Cobalt rehab hospital. He received his medical degree from University of Minnesota Medical School and has been in practice 43 years. He specializes in hospital medicine/hospitalist.
Education & Training
Abbott-Northwestern HospitalResidency, Internal Medicine, 1974 - 1977
University of Minnesota Medical SchoolClass of 1974
Certifications & Licensure
MN State Medical License 1971 - 2025
ND State Medical License 1971 - 2025
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
- Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) Start of enrollment: 2013 Aug 01
- 12-Week Study of Plecanatide for CIC (The CIC3 Study) Start of enrollment: 2013 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Dia...Elena A Christofides, Andrzej Stankiewicz, Douglas Denham, Diego Bellido, Edward Franek
Endocrine Practice. 2024-09-01 - 2 citationsImmunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 di...Elena A Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari
Diabetes, Obesity & Metabolism. 2024-06-01 - 523 citationsA 52-Week Placebo-Controlled Trial of Evolocumab in HyperlipidemiaDirk J. Blom, Tomas Hala, Michael A. Bolognese, Michael J. Lillestol, Phillip D. Toth
The New England Journal of Medicine. 2014-05-07
Press Mentions
Lillestol Research for Future GenerationsJune 10th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
